MANAGING YOUR BENLYSTA PATIENTS
It is important to set expectations and create individualised treatment plan for every patient.
In general, SLE patients eligible for BENLYSTA should:
- have active SLE 1
- be autoantibody positive (i.e. ANA or anti-dsDNA) based on routine laboratory assessment 1
- be taking standard therapies (for example, corticostreoids, antimalarials, NSAIDs, or other immunosuppressants) 1
- have a high degree of disease activity (e.g. positive anti-dsDNA and/or low complement) despite standard treatment for SLE and/or SELENA-SLEDAI score ≥ 10 1
There are no specific monitoring requirements for BENLYSTA, however, it is recommended to evaluate patients continuously, every 3 to 6 months. 2 To monitor SLE disease activity you can use the SELENA-SLEDAI tool.
It is recommended to administer BENLYSTA for at least 24 weeks before evaluating treatment success. 1 Discontinuation of treatment with BENLYSTA should be considered if there is no improvement in disease control after 6 months of treatment. 1